GSK up +1.35% percent right now. $GSK High is at 45.86 and the Low 45.47 with current volume of 2,057,741.
Recent News posted below.
GSK Glaxosmithkline Plc Recent Headline News
Aegerion to Acquire Myalept, Boost Portfolio - Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 48 mins ago
Aegerion Pharmaceuticals, Inc. (AEGR) has signed an agreement with AstraZeneca to acquire the latter's Myalept for $325 million.
BIIB: 323.13 (-4.74), AZN: 74.12 (+0.91), LLY: 67.94 (-0.41), AEGR: 21.46 (-0.11), GSK: 45.90 (+0.74)
When Is It Time To Accumulate Theravance?
Chris Lau - at Seeking Alpha - Tue Nov 11, 10:50AM CST
MRK: 59.33 (+0.52), AZN: 74.12 (+0.91), THRX: 12.93 (-0.51), TBPH: 18.02 (-0.30), GSK: 45.90 (+0.74)
Insys Q3 Beats Estimates, Helping Stock Rebound
at Investor's Business Daily - Tue Nov 11, 10:33AM CST
Specialty drugmaker Insys Therapeutics (INSY) beat Wall Street's Q3 estimates Tuesday, sending the stock up around 6% in early trading on the stock market today. Insys' revenue in the quarter totaled $58.3 million, double the year-earlier quarter and...
INSY: 40.87 (+3.81), GWPH: 74.72 (+0.77), TEVA: 58.24 (+0.20), GSK: 45.90 (+0.74)
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 10:15AM CST
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals ' Belviq and VIVUS 's Qsymia reported a combined 283,000 prescriptions in the third quarter, with...
PFE: 30.23 (+0.03), VVUS: 3.27 (+0.04), GSK: 45.90 (+0.74), ARNA: 4.50 (+0.10)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 117.19 (+0.25), GILD: 108.29 (+1.27), MRK: 59.33 (+0.52), DNDN: 0.16 (-0.02), AZN: 74.12 (+0.91), TEVA: 58.24 (+0.20), ABBV: 63.61 (-0.18), GSK: 45.90 (+0.74), BMY: 58.60 (-0.21), NVS: 92.56 (-0.07)
Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
M2 - Tue Nov 11, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g45smv/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global hospital pharmaceuticals market was valued at USD 2.65 billion in 2013 and is estimated to reach USD 10.90 billion in 2020, declining with a CAGR of (11.5)% from 2014 to 2020 The oncology segment accounts for the largest market share in 2013 wherein the immunomodulating agent holds the maximum share among other drug class commonly prescribed in hospital settings. Followed by oncology, cardiovascular disease account for the second largest share in which anti-cholinergic agent has the fastest declining growth rate. Decline in anti-cholinergic agent is primarily due to exclusivity loss of several high selling drugs such as VESIcare and Enablex which will lose their patent rights in 2015 and 2018 respectively. Geographically, North America region constitutes the largest market for global hospital pharmaceuticals market in 2013; however, Asia-Pacific is predicted to foresee the highest growth rate during the forecast period from 2014 to 2020. This growth has been attributed to large population base and increasing incidences of cardiovascular diseases and cancer incidences in both of the emerging regions. Moreover, according to the Central Bureau of Health Intelligence, the number of government hospitals in India increased from 4,571 in 2000 to 11,993 in 2011. Rising number of hospitals and growing awareness about branded drugs for treating chronic disease conditions is fueling the demand for hospital pharmaceuticals in these regions. Additionally, significant growth in medical tourism in Asia Pacific, Africa, the Middle East and Latin America would boost the hospital pharmaceuticals market. The leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis. Scope of the Report Cardiology - Anti-Adrenergic Drugs - Calcium Channel Blockers - Diuretic Drugs - Anti-Arrhythmic Drugs - Others Oncology - Alkylating Agents - Anti-Metabolites - Hormonal Agents - Immunomodulating Agents - Miscellaneous Drugs Nephrology and Urology - Diuretic Agents - Anti-Hypertensive Agents - Phosphate Binders - Anticholinergic Drugs - 5-Alpha Reductase Inhibitors Neurology - Anti-Anxiety Agents - Detail2Anti-Migraine Drugs - Antidepressant Drugs - Anti-Psychotic Drugs Pain - Anticonvulsant Drugs - Anesthetic Drugs - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Opioids - Non-Narcotics Analgesic Drugs Infection - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs - Antiparasite Drugs Global Hospital Pharmaceuticals Market, by Major Indications Cardiology - Coronary Heart Diseases - Stroke - High Blood Pressure - Heart Failure - Others Oncology - Lung Cancer - Breast Cancer - Colorectal Cancer - Prostate Cancer - Others Nephrology and Urology - Acute Kidney Failure - Chronic Kidney Diseases - Glomerular Diseases - Diabetes - Others Neurology - Epilepsy - Alzheimer;s Disease - Parkinson;s Disease - Multiple Sclerosis - Others Pain - Neuropathic Pain - Fibromyalgia - Osteoarthritis - Rheumatoid Arthritis - Cancer Pain Infection - Detail1Tuberculosis - Pneumonia - Hepatitis A - Hepatitis B - Candida Infection - Fungal Meningitis - Shigellosis - Amoebiasis - Other For more information visit http://www.researchandmarkets.com/research/g45smv/hospital
JNJ: 108.74 (-0.08), PFE: 30.23 (+0.03), MRK: 59.33 (+0.52), AZN: 74.12 (+0.91), LLY: 67.94 (-0.41), GSK: 45.90 (+0.74)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.33 (+0.52), AZN: 74.12 (+0.91), AMGN: 161.71 (-1.38), TEVA: 58.24 (+0.20), THRX: 12.93 (-0.51), GSK: 45.90 (+0.74), SNY: 47.07 (+0.88), REGN: 398.58 (+12.61), NVS: 92.56 (-0.07)
Global Huntington's Disease Therapeutics Market 2014-2018 - Novel Mechanisms Targeted by Pipeline Candidates
M2 - Tue Nov 11, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbsc46/global) has announced the addition of the "Global Huntington's Disease Therapeutics Market 2014-2018" report to their offering. The Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018. Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. One key trend emerging in this market is the targeting of novel mechanisms by pipeline molecules. Drugs with novel mechanisms might prove to be better treatment options and might affect the course of the disease through their neuroprotective effects. According to the report, one of the major drivers of the market is the unmet medical needs such as the lack of safe, efficacious, and disease-modifying treatments with regard to the treatment of Huntington's disease. Any drug that can cater to these needs is expected to drive the market during the forecast period. Further, the report states that the poor diagnosis rate is one of the major challenges in this market. This delays the initiation of therapy and affects the quality of life of the patient. Key Vendors - Lundbeck - Valeant Pharmaceuticals International Other Prominent Vendors - Auspex Pharmaceuticals - GlaxoSmithKline - Ipsen - Omeros - Palobiofarma - Pfizer - Prana Biotechnology - Raptor Pharmaceutical - Siena Biotech - SOM Biotech - Teva Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Prevalence of Huntington's Disease - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Clinical-stage Pipeline Candidates - Key Information of Clinical-stage Pipeline Candidates - Discontinued Clinical-stage Pipeline Drugs - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/lbsc46/global
RPTP: 10.68 (-0.04), TEVA: 58.24 (+0.20), ASPX: 25.91 (-0.33), GSK: 45.90 (+0.74), PRAN: 1.70 (-0.04), VRX.TO: 145.08 (-0.58)
Global Papillary Thyroid Cancer therapeutics Pipeline Report H2 2014 - Analysis of 6 Companies & 8 Drug Profiles
M2 - Tue Nov 11, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lcrf6q/papillary_thyroid) has announced the addition of the "Papillary Thyroid Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Papillary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Papillary Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Plexxikon Inc. - Novartis AG - Exelixis, Inc. - Deciphera Pharmaceuticals, LLC Drug Profiles - vandetanib - everolimus - cabozantinib s-malate - dabrafenib mesylate - rebastinib tosylate - PLX-7486 - CLM-3 - CLM-29 For more information visit http://www.researchandmarkets.com/research/lc...ry_thyroid
AZN: 74.12 (+0.91), GSK: 45.90 (+0.74), NVS: 92.56 (-0.07), EXEL: 1.79 (unch)
Avanir Faces Regulatory Setback, AVP-825 Could Be Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:40PM CST
Avanir Pharmaceuticals, Inc. (AVNR) received a disappointing preliminary feedback from the FDA regarding its new drug application for AVP-825.
LCI: 49.94 (-1.87), AVNR: 13.26 (+0.04), AUXL: 32.59 (-0.11), GSK: 45.90 (+0.74)
UCB to Sell Generics Business, Focus on Core Segments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:30PM CST
UCB SA (UCBJF) entered into an agreement with Advent International and Avista Capital Partners for the sale of its specialty generics subsidiary for $1.525 billion.
LCI: 49.94 (-1.87), LLY: 67.94 (-0.41), GSK: 45.90 (+0.74), NVS: 92.56 (-0.07)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.70 (+0.08), CRIS: 1.30 (-0.03), IMMU: 3.76 (+0.04), PCYC: 133.77 (-0.21), ONCY: 0.82 (-0.02), PFE: 30.23 (+0.03), LLY: 67.94 (-0.41), BMY: 58.60 (-0.21), GSK: 45.90 (+0.74), JNJ: 108.74 (-0.08), SNTA: 3.27 (+0.16), NVS: 92.56 (-0.07), XLRN: 33.82 (+1.56), ARRY: 3.85 (+0.01), CELGZ: 3.18 (-0.03), EXEL: 1.79 (unch)
Diabetic Foot Ulcers Therapeutics Pipeline Report H2 2014 - Analysis of 26 Companies & 37 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/b997sg/diabetic_foot) has announced the addition of the "Diabetic Foot Ulcers - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Derma Sciences, Inc. - GlaxoSmithKline plc - CardioVascular BioTherapeutics, Inc. - Stratatech Corporation - Tissue Med Biosciences - Reliance Life Sciences Pvt. Ltd. - Celgene Corporation - Kaken Pharmaceutical Co., Ltd. - CytoTools AG - NovaLead Pharma Pvt. Ltd. - FirstString Research, Inc. - Lumosa Therapeutics Co., Ltd. - CoDa Therapeutics, Inc. - Adocia - Plurogen Therapeutics, Inc. - EyeGene, Inc. - Izun Pharmaceuticals Corporation - MacroCure - Royer Biomedical, Inc. - Oneness Biotech Co., Ltd. - Aprogen, Inc. - Pergamum AB - Dipexium Pharmaceuticals LLC - Kasiak Research Pvt. Ltd. - Innovaxis - Grupo Praxis Pharmaceutical SA Drug Profiles - pexiganan acetate - DermaPro - trafermin - Recombinant Protein to Agonize Platelet Derived Growth Factor Receptor for Metabolic and Dermatology Diseases - ON-101 - DSC-127 - CureXcell - Granexin - Vivefoot - ReliDerm-DT - CVBT-141B - CODA-001 - PX-070101 - IZN-6D4 - CSTC-1 - PluroGel N - esmolol hydrochloride - gentamicin sulfate - GSK-1278863 - PDA-002 - TMBP-3 - coagulation factor XIVa (human) - AP-102 - Cyndacel-M - EG-Decorin - STD-06 - Nu-2 - Nu-3 - MT-003 - Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers For more information visit http://www.researchandmarkets.com/research/b9...betic_foot
DSCI: 8.40 (-0.10), DPRX: 11.05 (-0.10), GSK: 45.90 (+0.74), CELGZ: 3.18 (-0.03)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.63 (unch), IMGN: 10.06 (+0.11), AMGN: 161.69 (-1.40), LLY: 67.94 (-0.41), ONTX: 4.86 (unch), BMY: 58.60 (-0.21), GSK: 45.90 (+0.74), OXGN: 1.89 (-0.09), XLRN: 33.82 (+1.56), KPTI: 42.52 (-0.16), NVS: 92.56 (-0.07)
Theravance Biopharma Q3 Loss Widens Y/Y, Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:20AM CST
Theravance Biopharma reported a third-quarter 2014 loss of $1.72 per share.
AMAG: 34.67 (-0.24), TBPH: 18.02 (-0.30), GSK: 45.90 (+0.74), THRX: 12.93 (-0.51)
4 Stocks to Look at via Ebola Crisis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 9:43AM CST
Here are four stocks poised to benefit from bringing treatment for the dreaded virus Ebola.
MMM: 156.95 (-0.71), BCRX: 10.66 (-0.50), TK: 54.08 (-0.02), CCL: 40.53 (+0.22), DAL: 43.85 (+0.48), KMB: 113.21 (-0.71), DIS: 89.81 (+0.03), JBLU: 13.05 (-0.04), GSK: 45.90 (+0.74), MAR: 77.20 (+0.64), UAL: 54.66 (-0.17), LUV: 39.36 (+0.24), INO: 11.36 (+0.12), JNJ: 108.74 (-0.08), RCL: 67.74 (-0.24), APT: 3.05 (-0.06)
Is this MannKind Corporation's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Mon Nov 10, 7:32AM CST
The commercial success or failure of a new drug is rarely the result of a single event. So, predicting how a drug will perform prior to launch is perhaps more guesswork than most experts will openly admit. For example, after an arduous back and forth...
LLY: 67.94 (-0.41), GSK: 45.90 (+0.74), MNKD: 6.02 (+0.14), NVS: 92.56 (-0.07)
3 Healthcare Stocks With Unbeatable Dividends
Leo Sun, The Motley Fool - Motley Fool - Sun Nov 09, 9:42AM CST
Large pharmaceutical companies are often known for their generous dividends. Let's check in on three such income generators -- GlaxoSmithKline , AstraZeneca , and Pfizer -- to see if their businesses can back up their yields. Source:...
PFE: 30.23 (+0.03), AZN: 74.12 (+0.91), GSK: 45.90 (+0.74)
3 Biotech Stocks to Watch in November
Motley Fool Staff - Motley Fool - Sat Nov 08, 10:03AM CST
Investing in biotech companies can be tricky, especially for investors who don't have a scientific background or who don't completely understand the process of bringing new drugs to the marketplace. Fortunately, the Fool is here to help. We asked...
AVNR: 13.26 (+0.04), SGEN: 36.67 (-0.23), GILD: 108.29 (+1.27), ABBV: 63.62 (-0.17), GSK: 45.90 (+0.74)
Is New Hope Coming for Migraine Sufferers?
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 08, 9:05AM CST
The Centers for Disease Control and Prevention estimates there are 37 million migraine sufferers in the U.S., and that roughly 13 million prescriptions are written annually for triptan medicines to treat those people. B ut there's a big problem: too...
AVNR: 13.26 (+0.04), GSK: 45.90 (+0.74)
Recent News posted below.
GSK Glaxosmithkline Plc Recent Headline News
Aegerion to Acquire Myalept, Boost Portfolio - Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 48 mins ago
Aegerion Pharmaceuticals, Inc. (AEGR) has signed an agreement with AstraZeneca to acquire the latter's Myalept for $325 million.
BIIB: 323.13 (-4.74), AZN: 74.12 (+0.91), LLY: 67.94 (-0.41), AEGR: 21.46 (-0.11), GSK: 45.90 (+0.74)
When Is It Time To Accumulate Theravance?
Chris Lau - at Seeking Alpha - Tue Nov 11, 10:50AM CST
MRK: 59.33 (+0.52), AZN: 74.12 (+0.91), THRX: 12.93 (-0.51), TBPH: 18.02 (-0.30), GSK: 45.90 (+0.74)
Insys Q3 Beats Estimates, Helping Stock Rebound
at Investor's Business Daily - Tue Nov 11, 10:33AM CST
Specialty drugmaker Insys Therapeutics (INSY) beat Wall Street's Q3 estimates Tuesday, sending the stock up around 6% in early trading on the stock market today. Insys' revenue in the quarter totaled $58.3 million, double the year-earlier quarter and...
INSY: 40.87 (+3.81), GWPH: 74.72 (+0.77), TEVA: 58.24 (+0.20), GSK: 45.90 (+0.74)
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 10:15AM CST
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals ' Belviq and VIVUS 's Qsymia reported a combined 283,000 prescriptions in the third quarter, with...
PFE: 30.23 (+0.03), VVUS: 3.27 (+0.04), GSK: 45.90 (+0.74), ARNA: 4.50 (+0.10)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 117.19 (+0.25), GILD: 108.29 (+1.27), MRK: 59.33 (+0.52), DNDN: 0.16 (-0.02), AZN: 74.12 (+0.91), TEVA: 58.24 (+0.20), ABBV: 63.61 (-0.18), GSK: 45.90 (+0.74), BMY: 58.60 (-0.21), NVS: 92.56 (-0.07)
Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
M2 - Tue Nov 11, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g45smv/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global hospital pharmaceuticals market was valued at USD 2.65 billion in 2013 and is estimated to reach USD 10.90 billion in 2020, declining with a CAGR of (11.5)% from 2014 to 2020 The oncology segment accounts for the largest market share in 2013 wherein the immunomodulating agent holds the maximum share among other drug class commonly prescribed in hospital settings. Followed by oncology, cardiovascular disease account for the second largest share in which anti-cholinergic agent has the fastest declining growth rate. Decline in anti-cholinergic agent is primarily due to exclusivity loss of several high selling drugs such as VESIcare and Enablex which will lose their patent rights in 2015 and 2018 respectively. Geographically, North America region constitutes the largest market for global hospital pharmaceuticals market in 2013; however, Asia-Pacific is predicted to foresee the highest growth rate during the forecast period from 2014 to 2020. This growth has been attributed to large population base and increasing incidences of cardiovascular diseases and cancer incidences in both of the emerging regions. Moreover, according to the Central Bureau of Health Intelligence, the number of government hospitals in India increased from 4,571 in 2000 to 11,993 in 2011. Rising number of hospitals and growing awareness about branded drugs for treating chronic disease conditions is fueling the demand for hospital pharmaceuticals in these regions. Additionally, significant growth in medical tourism in Asia Pacific, Africa, the Middle East and Latin America would boost the hospital pharmaceuticals market. The leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis. Scope of the Report Cardiology - Anti-Adrenergic Drugs - Calcium Channel Blockers - Diuretic Drugs - Anti-Arrhythmic Drugs - Others Oncology - Alkylating Agents - Anti-Metabolites - Hormonal Agents - Immunomodulating Agents - Miscellaneous Drugs Nephrology and Urology - Diuretic Agents - Anti-Hypertensive Agents - Phosphate Binders - Anticholinergic Drugs - 5-Alpha Reductase Inhibitors Neurology - Anti-Anxiety Agents - Detail2Anti-Migraine Drugs - Antidepressant Drugs - Anti-Psychotic Drugs Pain - Anticonvulsant Drugs - Anesthetic Drugs - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Opioids - Non-Narcotics Analgesic Drugs Infection - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs - Antiparasite Drugs Global Hospital Pharmaceuticals Market, by Major Indications Cardiology - Coronary Heart Diseases - Stroke - High Blood Pressure - Heart Failure - Others Oncology - Lung Cancer - Breast Cancer - Colorectal Cancer - Prostate Cancer - Others Nephrology and Urology - Acute Kidney Failure - Chronic Kidney Diseases - Glomerular Diseases - Diabetes - Others Neurology - Epilepsy - Alzheimer;s Disease - Parkinson;s Disease - Multiple Sclerosis - Others Pain - Neuropathic Pain - Fibromyalgia - Osteoarthritis - Rheumatoid Arthritis - Cancer Pain Infection - Detail1Tuberculosis - Pneumonia - Hepatitis A - Hepatitis B - Candida Infection - Fungal Meningitis - Shigellosis - Amoebiasis - Other For more information visit http://www.researchandmarkets.com/research/g45smv/hospital
JNJ: 108.74 (-0.08), PFE: 30.23 (+0.03), MRK: 59.33 (+0.52), AZN: 74.12 (+0.91), LLY: 67.94 (-0.41), GSK: 45.90 (+0.74)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.33 (+0.52), AZN: 74.12 (+0.91), AMGN: 161.71 (-1.38), TEVA: 58.24 (+0.20), THRX: 12.93 (-0.51), GSK: 45.90 (+0.74), SNY: 47.07 (+0.88), REGN: 398.58 (+12.61), NVS: 92.56 (-0.07)
Global Huntington's Disease Therapeutics Market 2014-2018 - Novel Mechanisms Targeted by Pipeline Candidates
M2 - Tue Nov 11, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbsc46/global) has announced the addition of the "Global Huntington's Disease Therapeutics Market 2014-2018" report to their offering. The Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018. Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. One key trend emerging in this market is the targeting of novel mechanisms by pipeline molecules. Drugs with novel mechanisms might prove to be better treatment options and might affect the course of the disease through their neuroprotective effects. According to the report, one of the major drivers of the market is the unmet medical needs such as the lack of safe, efficacious, and disease-modifying treatments with regard to the treatment of Huntington's disease. Any drug that can cater to these needs is expected to drive the market during the forecast period. Further, the report states that the poor diagnosis rate is one of the major challenges in this market. This delays the initiation of therapy and affects the quality of life of the patient. Key Vendors - Lundbeck - Valeant Pharmaceuticals International Other Prominent Vendors - Auspex Pharmaceuticals - GlaxoSmithKline - Ipsen - Omeros - Palobiofarma - Pfizer - Prana Biotechnology - Raptor Pharmaceutical - Siena Biotech - SOM Biotech - Teva Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Prevalence of Huntington's Disease - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Clinical-stage Pipeline Candidates - Key Information of Clinical-stage Pipeline Candidates - Discontinued Clinical-stage Pipeline Drugs - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/lbsc46/global
RPTP: 10.68 (-0.04), TEVA: 58.24 (+0.20), ASPX: 25.91 (-0.33), GSK: 45.90 (+0.74), PRAN: 1.70 (-0.04), VRX.TO: 145.08 (-0.58)
Global Papillary Thyroid Cancer therapeutics Pipeline Report H2 2014 - Analysis of 6 Companies & 8 Drug Profiles
M2 - Tue Nov 11, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lcrf6q/papillary_thyroid) has announced the addition of the "Papillary Thyroid Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Papillary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Papillary Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Plexxikon Inc. - Novartis AG - Exelixis, Inc. - Deciphera Pharmaceuticals, LLC Drug Profiles - vandetanib - everolimus - cabozantinib s-malate - dabrafenib mesylate - rebastinib tosylate - PLX-7486 - CLM-3 - CLM-29 For more information visit http://www.researchandmarkets.com/research/lc...ry_thyroid
AZN: 74.12 (+0.91), GSK: 45.90 (+0.74), NVS: 92.56 (-0.07), EXEL: 1.79 (unch)
Avanir Faces Regulatory Setback, AVP-825 Could Be Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:40PM CST
Avanir Pharmaceuticals, Inc. (AVNR) received a disappointing preliminary feedback from the FDA regarding its new drug application for AVP-825.
LCI: 49.94 (-1.87), AVNR: 13.26 (+0.04), AUXL: 32.59 (-0.11), GSK: 45.90 (+0.74)
UCB to Sell Generics Business, Focus on Core Segments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:30PM CST
UCB SA (UCBJF) entered into an agreement with Advent International and Avista Capital Partners for the sale of its specialty generics subsidiary for $1.525 billion.
LCI: 49.94 (-1.87), LLY: 67.94 (-0.41), GSK: 45.90 (+0.74), NVS: 92.56 (-0.07)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.70 (+0.08), CRIS: 1.30 (-0.03), IMMU: 3.76 (+0.04), PCYC: 133.77 (-0.21), ONCY: 0.82 (-0.02), PFE: 30.23 (+0.03), LLY: 67.94 (-0.41), BMY: 58.60 (-0.21), GSK: 45.90 (+0.74), JNJ: 108.74 (-0.08), SNTA: 3.27 (+0.16), NVS: 92.56 (-0.07), XLRN: 33.82 (+1.56), ARRY: 3.85 (+0.01), CELGZ: 3.18 (-0.03), EXEL: 1.79 (unch)
Diabetic Foot Ulcers Therapeutics Pipeline Report H2 2014 - Analysis of 26 Companies & 37 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/b997sg/diabetic_foot) has announced the addition of the "Diabetic Foot Ulcers - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Derma Sciences, Inc. - GlaxoSmithKline plc - CardioVascular BioTherapeutics, Inc. - Stratatech Corporation - Tissue Med Biosciences - Reliance Life Sciences Pvt. Ltd. - Celgene Corporation - Kaken Pharmaceutical Co., Ltd. - CytoTools AG - NovaLead Pharma Pvt. Ltd. - FirstString Research, Inc. - Lumosa Therapeutics Co., Ltd. - CoDa Therapeutics, Inc. - Adocia - Plurogen Therapeutics, Inc. - EyeGene, Inc. - Izun Pharmaceuticals Corporation - MacroCure - Royer Biomedical, Inc. - Oneness Biotech Co., Ltd. - Aprogen, Inc. - Pergamum AB - Dipexium Pharmaceuticals LLC - Kasiak Research Pvt. Ltd. - Innovaxis - Grupo Praxis Pharmaceutical SA Drug Profiles - pexiganan acetate - DermaPro - trafermin - Recombinant Protein to Agonize Platelet Derived Growth Factor Receptor for Metabolic and Dermatology Diseases - ON-101 - DSC-127 - CureXcell - Granexin - Vivefoot - ReliDerm-DT - CVBT-141B - CODA-001 - PX-070101 - IZN-6D4 - CSTC-1 - PluroGel N - esmolol hydrochloride - gentamicin sulfate - GSK-1278863 - PDA-002 - TMBP-3 - coagulation factor XIVa (human) - AP-102 - Cyndacel-M - EG-Decorin - STD-06 - Nu-2 - Nu-3 - MT-003 - Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers For more information visit http://www.researchandmarkets.com/research/b9...betic_foot
DSCI: 8.40 (-0.10), DPRX: 11.05 (-0.10), GSK: 45.90 (+0.74), CELGZ: 3.18 (-0.03)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.63 (unch), IMGN: 10.06 (+0.11), AMGN: 161.69 (-1.40), LLY: 67.94 (-0.41), ONTX: 4.86 (unch), BMY: 58.60 (-0.21), GSK: 45.90 (+0.74), OXGN: 1.89 (-0.09), XLRN: 33.82 (+1.56), KPTI: 42.52 (-0.16), NVS: 92.56 (-0.07)
Theravance Biopharma Q3 Loss Widens Y/Y, Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:20AM CST
Theravance Biopharma reported a third-quarter 2014 loss of $1.72 per share.
AMAG: 34.67 (-0.24), TBPH: 18.02 (-0.30), GSK: 45.90 (+0.74), THRX: 12.93 (-0.51)
4 Stocks to Look at via Ebola Crisis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 9:43AM CST
Here are four stocks poised to benefit from bringing treatment for the dreaded virus Ebola.
MMM: 156.95 (-0.71), BCRX: 10.66 (-0.50), TK: 54.08 (-0.02), CCL: 40.53 (+0.22), DAL: 43.85 (+0.48), KMB: 113.21 (-0.71), DIS: 89.81 (+0.03), JBLU: 13.05 (-0.04), GSK: 45.90 (+0.74), MAR: 77.20 (+0.64), UAL: 54.66 (-0.17), LUV: 39.36 (+0.24), INO: 11.36 (+0.12), JNJ: 108.74 (-0.08), RCL: 67.74 (-0.24), APT: 3.05 (-0.06)
Is this MannKind Corporation's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Mon Nov 10, 7:32AM CST
The commercial success or failure of a new drug is rarely the result of a single event. So, predicting how a drug will perform prior to launch is perhaps more guesswork than most experts will openly admit. For example, after an arduous back and forth...
LLY: 67.94 (-0.41), GSK: 45.90 (+0.74), MNKD: 6.02 (+0.14), NVS: 92.56 (-0.07)
3 Healthcare Stocks With Unbeatable Dividends
Leo Sun, The Motley Fool - Motley Fool - Sun Nov 09, 9:42AM CST
Large pharmaceutical companies are often known for their generous dividends. Let's check in on three such income generators -- GlaxoSmithKline , AstraZeneca , and Pfizer -- to see if their businesses can back up their yields. Source:...
PFE: 30.23 (+0.03), AZN: 74.12 (+0.91), GSK: 45.90 (+0.74)
3 Biotech Stocks to Watch in November
Motley Fool Staff - Motley Fool - Sat Nov 08, 10:03AM CST
Investing in biotech companies can be tricky, especially for investors who don't have a scientific background or who don't completely understand the process of bringing new drugs to the marketplace. Fortunately, the Fool is here to help. We asked...
AVNR: 13.26 (+0.04), SGEN: 36.67 (-0.23), GILD: 108.29 (+1.27), ABBV: 63.62 (-0.17), GSK: 45.90 (+0.74)
Is New Hope Coming for Migraine Sufferers?
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 08, 9:05AM CST
The Centers for Disease Control and Prevention estimates there are 37 million migraine sufferers in the U.S., and that roughly 13 million prescriptions are written annually for triptan medicines to treat those people. B ut there's a big problem: too...
AVNR: 13.26 (+0.04), GSK: 45.90 (+0.74)
